In this study, we used a combination of pharmacological and genetic approaches to determine which endogenous sphingolipid is the likely mediator of growth inhibition. When cells were treated with exogenous phytosphingosine (PHS, 20 M) or structurally similar or metabolically related molecules, including 3-ketodihydrosphingosine, dihydrosphingosine, C 2 -phytoceramide (PHC), and stearylamine, only PHS inhibited growth. Also, PHS was shown to inhibit uptake of uracil, tryptophan, leucine, and histidine. Again this effect was specific to PHS. Because of the dynamic nature of sphingolipid metabolism, however, it was difficult to conclude that growth inhibition was caused by PHS itself. By using mutant yeast strains defective in various steps in sphingolipid metabolism, we further determined the specificity of PHS. The elo2⌬ strain, which is defective in the conversion of PHS to PHC, was shown to have slower biosynthesis of ceramides and to be hypersensitive to PHS (5 M), suggesting that PHS does not need to be converted to PHC. The lcb4⌬ lcb5⌬ strain is defective in the conversion of PHS to PHS 1-phosphate, and it was as sensitive to PHS as the wild-type strain. The syr2⌬ mutant strain was defective in the conversion of DHS to PHS. Interestingly, this strain was resistant to high concentrations of DHS (40 M) that inhibited the growth of an isogenic wild-type strain, demonstrating that DHS needs to be converted to PHS to inhibit growth. Together, these data demonstrate that the active sphingolipid species that inhibits yeast growth is PHS or a closely related and yet unidentified metabolite.Certain sphingolipid metabolites including ceramide, sphingosine, and sphingosine 1-phosphate have pleiotropic effects on cellular growth and proliferation. The yeast Saccharomyces cerevisiae has emerged as an excellent model system for studying sphingolipid-mediated signal transduction. First, compared with over 300 different kinds of sphingolipids found in mammalian cells, there is only a limited number of sphingolipid species in the yeast, which simplifies lipid analysis (2, 3). Moreover, the basic structure, biosynthesis, and metabolism of sphingolipids are well conserved between mammalian and yeast systems. Second, many yeast genes in the sphingolipid biosynthetic and metabolic pathways have been cloned, providing opportunities for studying the effects of endogenous sphingolipids using genetics tools. Finally, although this is not exclusive to sphingolipid studies, yeast genetics provide excellent tools to identify and characterize components in signal transduction pathways (4 -6).Evidence for conservation of the sphingolipid signaling pathway in yeast comes from several studies. These include demonstrating that D-erythro-ceramide inhibited yeast cell growth in liquid culture and activated a protein phosphatase 2A that could be inhibited by okadaic acid (7). Later, Nickels and Broach (8) showed that ceramide inhibited yeast cell growth by arresting cell cycle at G 1 phase and that ceramide-activated protein phosphatase is com...